TRANSACTIVATION OF THE HUMAN P53 TUMOR-SUPPRESSOR GENE BY C-MYC/MAX CONTRIBUTES TO ELEVATED MUTANT P53 EXPRESSION IN SOME TUMORS

被引:123
|
作者
ROY, B [1 ]
BEAMON, J [1 ]
BALINT, E [1 ]
REISMAN, D [1 ]
机构
[1] UNIV S CAROLINA, DEPT BIOL SCI, COLUMBIA, SC 29208 USA
关键词
D O I
10.1128/MCB.14.12.7805
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elevated levels of mutant forms of the p53 tumor suppressor are a hallmark of many transformed cells. Multiple mechanisms such as increased stability of the protein and increased transcription of the gene can account for elevated p53 expression. Recent findings indicate that c-Myc/Max heterodimers can bind to an essential CA(C/T)GTG-containing site in the p53 promoter and elevate its expression. We have addressed the possibility that elevated mutant p53 expression is due to deregulated c-Myc expression. Here we demonstrate that the human p53 promoter is transactivated by high c-Myc expression and repressed by high Max expression. In examining the relative levels of c-Myc and p53 in human Burkitt's lymphomas and other B-lymphoid lines, we found that there is a correlation between the levels of c-Myc protein and p53 mRNA expression. In particular, cells that express very low levels of c-Myc protein also express low levels of p53 mRNA, while cells that express high levels of c-Myc tend to express high levels of p53 mRNA. To determine whether the p53 gene can be a target for c-Myc in vivo, we assayed the effects of antisense c-myc RNA on the levels of endogenous p53 mRNA. The results indicate that the presence of antisense c-myc RNA leads to a reduction in the levels of c-Myc protein, p53 mRNA, and expression from the p53 promoter. Taken together, our findings support a direct role for c-Myc in elevating expression of the mutant p53 gene in some tumors.
引用
收藏
页码:7805 / 7815
页数:11
相关论文
共 50 条
  • [21] On the clinical significance of the tumor-suppressor gene p53 in head and neck tumors
    Preisler, V
    Kirchner, S
    Hagen, R
    HNO, 1997, 45 (09) : 659 - 662
  • [22] IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY
    CHANG, FJ
    SYRJANEN, S
    SYRJANEN, K
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 1009 - 1022
  • [23] THE P53 TUMOR-SUPPRESSOR GENE IN BREAST-CANCER
    ELLEDGE, RM
    ALLRED, DC
    BREAST CANCER RESEARCH AND TREATMENT, 1994, 32 (01) : 39 - 47
  • [24] p53 tumor-suppressor gene: Clues to molecular carcinogenesis
    Wang, XW
    Harris, CC
    JOURNAL OF CELLULAR PHYSIOLOGY, 1997, 173 (02) : 247 - 255
  • [25] P53 AND RB TUMOR-SUPPRESSOR GENE ALTERATIONS IN RETINOBLASTOMA
    ITO, M
    MISHIMA, HK
    INAI, K
    ITO, T
    AKIYAMA, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 (06) : 1329 - 1332
  • [26] CLINICAL-APPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE
    DIAMANDIS, EP
    CLINICA CHIMICA ACTA, 1995, 237 (1-2) : 79 - 90
  • [27] THE P53 TUMOR-SUPPRESSOR GENE AND ITS SIGNIFICANCE FOR DERMATOLOGY
    LUBBE, J
    KLEIHUES, P
    BURG, G
    HAUTARZT, 1994, 45 (11): : 741 - 745
  • [28] EXPRESSION OF THE P53 TUMOR-SUPPRESSOR GENE-PRODUCT IS A DETERMINANT OF CHEMOSENSITIVITY
    PETTY, RD
    CREE, IA
    SUTHERLAND, LA
    HUNTER, EM
    LANE, DP
    PREECE, PE
    ANDREOTTI, PE
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 199 (01) : 264 - 270
  • [29] THE P53 TUMOR SUPPRESSOR GENE
    LEVINE, AJ
    MOMAND, J
    FINLAY, CA
    NATURE, 1991, 351 (6326) : 453 - 456
  • [30] P53 TUMOR SUPPRESSOR GENE
    SOUSSI, T
    BULLETIN DU CANCER, 1993, 80 (02) : 96 - 101